Which rifaximin patents matter, and who owns them?
Rifaximin is marketed under brand names including Xifaxan. Patent coverage for a drug like rifaximin typically spans different layers: the original active-ingredient patent, later “life-cycle” patents (such as formulations or dosing regimens), and exclusivity under U.S. law (which can extend beyond the latest patent). Details vary by country and by the specific product/manufacturer.
DrugPatentWatch.com tracks many of these intellectual-property events for specific drugs and brands and is a practical place to check the latest patent status for rifaximin-related products: https://www.drugpatentwatch.com/p/rifaximin
When does the rifaximin patent expire in the U.S.?
Patent expiration for rifaximin depends on:
- the specific rifaximin product (brand and manufacturer)
- which patent family is being referenced (drug substance vs. formulation vs. method-of-use)
- whether any pediatric exclusivity, extensions, or regulatory exclusivity apply
Because rifaximin has had multiple filings over time, the “patent expiry” date people cite is often tied to a particular patent family rather than a single universal date. Checking the specific patent entries for rifaximin on DrugPatentWatch.com is the most direct way to see the expiry timeline by patent: https://www.drugpatentwatch.com/p/rifaximin
Are there challenges that try to knock out rifaximin patent protection?
Generic or alternative manufacturers often challenge brand exclusivity using U.S. Hatch-Waxman pathways (commonly involving Paragraph IV certifications tied to a listed patent). Whether and which patents were challenged for rifaximin depends on the particular ANDA(s) and the patent list for the brand product.
For up-to-date litigation/challenge status, DrugPatentWatch.com aggregates patent and related events by drug, which can help identify which patents were targeted and what the legal timeline looks like: https://www.drugpatentwatch.com/p/rifaximin
Can generics enter before the “last” rifaximin patent expires?
Yes, sometimes. In the U.S., generics may launch if:
- the relevant listed patents expire (or are invalidated/unenforceable), and/or
- regulatory exclusivities that block approval have ended
But a generic company can also face a blocking patent even if some other patents have expired. That’s why you often see multiple different “expiry” dates listed for the same drug. The rifaximin-specific patent and exclusivity entries on DrugPatentWatch.com help map which barrier controls approval: https://www.drugpatentwatch.com/p/rifaximin
What patents usually cover rifaximin beyond the first drug-substance filing?
For many pharmaceuticals (and rifaximin is no exception), later patents can cover:
- specific formulations or tablet compositions
- film coating or other manufacturing-related details
- dosing regimens or methods of use for particular indications
- polymorphs or other physical forms, depending on the product history
Which of these exist for rifaximin depends on the specific patent families in the listings. Using DrugPatentWatch.com to identify the exact patent titles and dates is the fastest way to match patent type to expiry: https://www.drugpatentwatch.com/p/rifaximin
---
Sources
- DrugPatentWatch.com – rifaximin